Company Overview
Cellectis S.A. operates as a clinical stage biotechnological entity dedicated to developing products grounded in gene-editing technology. The company's portfolio includes allogeneic chimeric antigen receptor T-cells product candidates within the immuno-oncology sector, alongside gene therapy product candidates targeting other therapeutic indications. This biotechnology firm functions within the broader healthcare industry, where it leverages proprietary technologies to advance novel treatments for various medical conditions. The company currently maintains a market capitalization of $338.99M and reported annual revenue of $79.59M over the trailing twelve months, while its employee count is listed as N/A. These valuation and revenue figures indicate that Cellectis holds a position in the biotechnology landscape characterized by significant research and development activity, reflected in its revenue generation despite the absence of profitability, which is typical for firms in the clinical stage of development.
Financial Health
The company reported a revenue of $79.59M for the trailing twelve months, a net income of $-67,593,000, and an EBITDA of $-21,750,000. The substantial gap between the positive revenue of $79.59M and the negative net income of $-67,593,000 reveals a cost structure where operating expenses significantly exceed gross revenue, resulting in a net loss. Cellectis generated free cash flow of $-25,282,376, which indicates that the company is currently burning cash to fund its clinical trials and operational activities rather than generating surplus liquidity. This negative free cash flow suggests limited financial flexibility in the short term, relying on existing cash reserves to sustain operations. The company exhibits a gross margin of 100.0%, an operating margin of -142.1%, and a profit margin of -84.9%. The 100.0% gross margin implies that the cost of goods sold is negligible relative to revenue, while the negative operating and profit margins highlight the heavy investment in research, development, and administrative costs required to bring products to market. In terms of capital structure, the company holds $206.38M in cash against $86.69M in debt, resulting in a debt-to-equity ratio of 114.22. Although the company carries debt, the cash balance exceeds total liabilities, suggesting a balance sheet that is well-capitalized despite the high leverage ratio. The current ratio stands at 1.62, which indicates that the company possesses sufficient short-term assets to cover its short-term obligations with a margin of safety. Furthermore, the return on equity is -65.3% and the return on assets is -5.8%, metrics that reveal the company is currently destroying shareholder value and utilizing assets at a loss, a common scenario for early-stage biotechnology companies before product commercialization.
Valuation Assessment
Cellectis S.A. displays a trailing P/E ratio of N/A and a forward P/E of -5.44. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market does not assign a traditional earnings-based multiple due to the company's consistent losses, and the negative forward multiple reflects expectations of continued negative earnings in the near future. The price-to-book ratio is 3.21, which indicates that the market is pricing the company at more than three times its book value, suggesting a premium assigned to its intellectual property and potential future value despite current losses. Additionally, the price-to-sales ratio is 4.26 and the EV/EBITDA is -5.74. These alternative valuation metrics suggest that investors are valuing the company primarily on its revenue generation and asset base rather than earnings, as the negative EV/EBITDA underscores the lack of positive earnings power at this stage. The stock's 52-week high is $5.48 and the 52-week low is $1.10. Without a specific current price provided in the facts to calculate a precise percentage, the trading range is defined by these extremes, illustrating the volatility inherent in the biotechnology sector. The beta value is 2.85, which means the stock price is expected to be nearly three times more volatile than the broader market, indicating that the asset carries significantly higher systematic risk for investors.
Growth & Income
The company reported a revenue growth rate of -19.5% year-over-year, while the earnings growth rate is N/A. The negative revenue growth indicates a contraction in sales, and since there are no earnings to compare against, the decline in revenue is the primary indicator of performance trajectory. As a non-dividend payer, Cellectis S.A. does not distribute a dividend yield or maintains a payout ratio of 0.0%. Consequently, the company reinvests all available earnings, or in this case, retained losses, into growth initiatives such as clinical trials and product development rather than paying dividends to shareholders. The overall growth and income profile is characterized by negative revenue momentum and a lack of dividend income, reflecting a strategy focused on long-term product development rather than immediate financial returns to investors.